Evaxion A/S

Thank you for joining us for Evaction's business update following the reporting of our 2025 full year financial results yesterday. And apologies that this call is 24 hours later than we anticipated, but for technical reasons, we're delighted to be here today. My name is Helen Tate and I am honored to be leading this call for the first time as Evaction's CEO. We'll move to the first slide. Okay. So on today's call, we will review the achievements of 2025 and touch on the milestones we anticipate for 2026. Our chief scientific officer, Brigitte Renaud, will then walk through our key R&D updates from the year, including the latest innovations from our AI immunology platforms, after which our CFO, Thomas Schmidt, will walk through our 2025 financial results before we close with a few concluding remarks and take questions. Right, moving to the next slide. And of course, our comments and presentation today may contain forward-looking statements, and all participants on today's call are referred to our filed SEC statements, and specifically, our most recent 20th Annual Report for 2025 filed yesterday. So moving to the next slide, I will start with our 2025 achievements

our 2026 milestones.

In 2025, we were very pleased to report tremendous progress across all pillars of the company. First of all, in business development, we were delighted with the progress in our collaboration with MSD and our infectious disease portfolio, with the decision by Merck to exercise its option over our EVX B3 program candidates. Whilst the target for this programme is not disclosed, we are very proud that this represents the first in licensing to our knowledge of an infectious disease vaccine candidate identified and validated to an AI discovery platform. Whilst MSD chose not to exercise its option over our EVXB2 candidate in Gonorrhea, we remain very excited about the data and the prospects for this programme, over which we have retained full rights and have seen significant interest. We were also pleased to enter into a collaboration with the Gates Foundation on the design of a new polio vaccine and are also seeing significant interest in our platform of pipeline programs more broadly from a number of parties. In R&D, we were very pleased to be able to present very positive two-year phase two data at ESMO on our EVX01 program with a personalized neoantigen directed cancer vaccine in advanced melanoma patients. We also presented preclinical data at ASH on our first cancer vaccine to a shared antigen directed to a conserved endogenous retroviral or EBR element that we have identified in AML patients with our EVXO4 program. In our infectious disease portfolio, we were also able to move forward a new program with candidates identified from our AI immunology platform against Group A Streptococcus. On the platform The team has continued to innovate and use the platform to not only identify optimal vaccine candidates, but improve their design biology for product delivery for us in our new automated module. And Begita will touch on all of these achievements shortly. We were also honored by the recognition of our AI immunology platform by the Galien Foundation for AI advances in human health. And finally, we were very pleased to see the capital influx to the business last year through financing, business development, and the use of our ATM, which now gives us action a cash run way to the second half of twenty twenty seven. And Thomas will talk more to this later. So moving to the next slide. Just as a reminder. I've action has built a broad, novel product versus pipeline of assets from its unique immunology platform, clinically validated with the cancer vaccine space without the XO1 peptide based vaccine in advanced melanoma. but supported by assets and data on DNA and RNA platforms, and together with a preclinical pipeline of infectious disease vaccine candidates focused on challenging targets remaining intractable with conventional approaches and subject to significant medical need. On to the next slide. This unique capability with AI immunology is something that we have also begun to investigate within the autoimmune field, given a wider range of diseases driven by autoimmune attacks. and the direct applicability of our platform to focus on immune mechanisms in disease. Autoimmune diseases affect over 14 million patients annually in the US and are characterized by chronic debilitating conditions with treatment options focused primarily on the symptoms rather than the underlying cause of disease. Moving on to the next slide. This is why we believe our AI immunology platform is strongly positioned to focus on underlying disease mechanisms with greater specificity to identify autoimmune disease targets, which can be approached in different ways. There'll be more to come on this later in the year. And finally, in the next slide, turning to our 2026 milestone, this year we will be updating on our EVX01 program with additional biomarker and immunogenicity data, AACR. and then the clinical data, three-year data, later towards the end of the year. We will be talking more about the autoimmune applications of our AI immunology platform and bringing forward data on our new EVXB4 candidates in Group A Streptococcus in the second half of the year. And finally, be ready to submit our regulatory application for our next EVXO4 candidate for the shared herb antigens in AML by the end of the year. And throughout, we remain committed to deriving value from both our platform and our pipeline assets through partnership for our shareholders and patients. I'll now hand over to Birgitta to update you further on our R&D achievements.

Thank you, Helen. So 2025 marked a turning point with significant advancement across our R&D pipeline and also our AI platform. And additionally, as Helen alluded to, we also entered into the in-licensing agreement with MSD on the DVX-B3 program. So our 2025 focus has been on strengthening our platform's predictive power, maturing key R&D assets, and on building the foundation for future partnerships. So the 2025 achievements position as well as we move towards the data-rich milestones in 2026 that Helen just presented. So with that, I'll begin by walking through individual key programs and platform development.

So next slide, please.

EVX01, our personalized peptide-based cancer vaccine in advanced melanoma, continues to deliver strong clinical data. So our two-year phase two data presented at an oral session at ESMO in October showed strong clinical outcome, including a high objective response rate of 75% and complete response rate of 25. Notably, 92% of the responders remained in response at this two-year mark. Key biomarker data included the very high immunogenicity hit rate with 81% of all the individual new antigen administered across patients giving rise to a specific T cell response. So this very impressive hit rate outcompetes data from similar programs conducted by others. And this truly underlines the precision of our AI immunology platform to identify relevant vaccine targets. Two key milestones are expected for this program, as Helen also alluded to, additional biomarker and immunogenicity data expected in the first half of 26, and we also plan to communicate the three-year data from a subset of patients that are currently in an expansion part of the Phase II study, and that will be reported in the second half of 26. So importantly, we aim to conduct future trials in partnership, ensuring the broadest possible impacts for patients. So moving to the next slide and EDX04, our off-the-shelf therapeutic vaccine for acute myeloid leukemia, or AML, we have generated a compelling preclinical evidence supporting its development. In this program, we are focusing on a completely novel class of tumor antigens, so-called endogenous spectroviruses, or ERVs, that are selectively and highly expressed in AML blasts, making them attractive as therapeutic targets. So with AI Immunology, we have identified millions of short ERV fragments from patient sequencing tumor data and designed the EVX for vaccines with 16 optimal antigen fragments selected based on cross-patient relevance and also on their immunological potential. So key data include in vitro vaccination studies demonstrating that all of these 16 fragments in the vaccine induce a strong specific immune response And further, that EVX04 prevents tumor growth in several mouse tumor models and induces strong T cell responses. So again, these findings reinforces the power of our platform, and here we have expanded it to uncover unique tumor antigens that are not accessible through traditional discovery methods. Next slide, please. As we progress towards clinical readiness for evaxopal, we have completed key steps including antigen selection and lead development. We have conducted preclinical efficacy studies and are currently conducting further human cell-based translational assays. CMC work and GMP manufacturing are advancing according to plan. And the next major milestone for this program is the submission of the clinical trial application in the second half of 26, which enabled first in human testing. So this program is a prime example of how AI immunology accelerates vaccine design from concept to clinic. So next slide, please. Now turning to our key infectious disease programs. So after retaining the full global rights to EVXB2 late last year, we are now fully in control of the development of this highly differentiated vaccine candidate targeting Neisseria gonorrhea. So our preclinical data package is strong and comprehensive, demonstrating significant protection in a mouse infectious model. We have demonstrated broad efficacy against 50 clinically relevant isolates reflecting coverage across diverse strains and further induction of significant humoral and cellular responses in mice. And we have also demonstrated a well-established mechanism of action supported by potent antibody-dependent complement-mediated killing. So collectively, these results position EVXB2 as one of the most advanced and differentiated infectious disease preclinical gonorrhea vaccine candidates in an area of high unmet need where no approved vaccine exists today. So given the strength of our data, we see a clear opportunity to engage with potential partners to progress the program towards clinical development. So next slide, please. So another of our key infectious disease vaccine programs is EVXV1. In this program, we are developing a multi-target vaccine against cytomegalovirus or CMV. And instead of relying on a single glycoprotein or limited set of glycoproteins, The program integrates both these well-described glycoproteins and novel antigens to target the virus from multiple complementary angles. So this broad multi-component strategy is designed to enhance vaccine efficacy and also to reduce the risk of viral escape. So we have applied AI immunology for both antigen optimization of the known glycoproteins and for identification of truly novel antigens. So first, we improved these established CMV antigens that are essential for virus neutralization. And as part of this, we have engineered the glycoprotein B antigen by locking it in a pre-fusional state. And this AI immunology-designed construct has demonstrated a superior neutralization capacity compared to the native protein. Secondly, we are identifying and validating entirely novel antigens, and several of these have already demonstrated the ability to inhibit viral entry, and further, we are characterizing them at the moment. So, supported by this strong preclinical data, EVXV1 represents a highly promising program for continued development and for future partnership discussions. Next slide, please. So, now turning to the recent development of our AI immunology platform. So, our AI immunology platform continues to expand in capability, so the platform integrates multi-omic data set to generate ranked antigen lists within 24 hours. So in October last year, we launched an automated vaccine design module enabling sequence and structural optimization directly from the short-listed antigens. And this end-to-end automation significantly reduced cost, development time, and also risk. So next slide, please. So more specifically, the automated module enhances design of soluble antigen constructs, enabling higher expression, better formulation, and improved manufacturability. So this capability directs the design of soluble antigen constructs and also solubilizing antigens using inverse folding, producing more reliable antigen constructs than the wild-type variants. The result is a faster and more cost-effective design cycle, fully integrated into our antigen discovery and vaccine optimization workflow. So this strengthens the foundation for all of our programs across oncology and infectious diseases. So in conclusion, we have seen strong progress across our platform and our R&D pipeline, and we are encouraged by the momentum. And we look forward to keeping you updated as we advance through 2026. And with that, I'll now hand over to Thomas, who will walk us through our financial results.

Yes, thank you, Birgitte. And also a warm welcome from my side to our call today. And I will now walk you through the financial results for 2025. So turning to the next page, we have throughout 2025 been really successful in expanding on our cash runway and also strengthening on our equity side. This has happened throughout the year through public offering and the use of ATM. We did in January, followed by the MSD exercise fee and the ATM use in September. And furthermore, the exercise of investor warrants from our January offering in October and November. all summing up to a cash inflow of 32 million US. Furthermore, as also shown on this slide, our EIB debt to equity conversion done in July of 4.1 million US. We've reduced certainly our cash, future cash out, and thereby certainly also expanding and extending our cash runway. And finally, with our filing in December of our prospectus supplement regarding our ATM, it has now created us with further flexibility and options as we move forward with expanding our pipeline and platform also. So really, really underlying to strong execution throughout the year. And turning to the next slide, that also leads into the highlights of 2025, where we really have delivered on all the targets that we set, and we are progressing towards our aim of becoming a sustainable self-funding business. Both revenue and costs have improved while at the same time we are continuing to invest in our platform and in our pipeline programs. As just mentioned on the previous slide, activities and execution of the MSD deal, the EIB debt conversion, our ATM and capital market activities have not only improved our cash position and runway, but has also significantly strengthened our equity. And with the improved cash runway and equity, equity, we have created more stability and certainly have also reduced uncertainty. So I think that is really, really also a highlight for 25. And again, with the update of 380M, we have removed the constraints of baby shelf and also provides us far better flexibility and options in support of our long-term strategic initiatives and also the long-term plans we do have. Next slide is on our profit and loss statement. As I just mentioned, Revenue has improved, but also we've improved on our operational costs. So we've actually been successful in lowering our operational spend whilst at the same time delivering on the quality that we would want to do from a pipeline and platform perspective. Revenue certainly stems from our MSD option exercise, but also important to mention, we also had a grant from the Gates Foundation that also has come in 2025. Apologies. Net financial position of 0.6 million is driven by a premium that we received from our debt conversion, debt to equity conversion from the EIB. And against that goes remeasurement of a derivative liability as some of our warrants or our warrants from the public offering in January were in a different format. uh exchange uh setting so the usd versus our reporting of dkk net loss for the year 7.7 million certainly and at bettering compared to uh last year and as i said before also a good step on the way of becoming a self-funding and profitable business next slide on the Balance sheet items, we ended the year with a cash position of 23 million US with a runway that now is extended into half year two of 2027. Certainly also a significant improvement compared to last year. And this, of course, will be used for operations expenses and investing into our platform and pipeline. We currently have a total outstanding ADS of 8.3 million when assuming that all shares have been converted into ADSs. We've also, through the investor warrant exercises, exercise has been reducing the outstanding warrants in terms of ADSs by 1 million, which leaves another 2.8 million warrants outstanding, so also an improvement in that and really drives in the right direction. So in summary, from a financial position, we have during 2025 established a far better foundation that really makes us, puts us in a good position to continue our execution of strategy and business for 26 and the years beyond. I hand it back to Helen for some final concluding remarks.

Thanks, Thomas. And just moving to the last slide.

In summary, 2025 was a year of strong operational momentum for EVACTION in which we achieved several key milestones. Overall, we strengthen the business considerably to the validation of our strategy with our AI immunology platform, delivering on both data and partnerships. This in turn has enabled us to both strengthen our financial position and consolidate our position as a leader in AI-based drug discovery, design, and early development. With a number of potential partnership discussions ongoing, we are already funded into the second half of 2027 to the financial milestones achieved in 2025. So we're in a good position to move forward through 2026. With that, I'll hand over to the operator for questions.

Thank you. To ask a question, you will need to press star 1 and 1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1 and 1 again.

Our first question today,

comes from the line of Thomas Flaten from Lake Street Capital Markets. Please go ahead.

Hi, everybody. Thanks for taking the questions. Maybe to start broadly, Helen, you've been in the seat now for a few months. I'm just curious if you could provide some overarching commentary on what you have implemented or are going to implement You know any changes to strategy and any bigger picture notes like that that could that could help us with context of your tenure Sure, thanks.

Thanks. Thanks for the question. Yep. I joined at the end of November last year So the last three months have flown by but I already had a strong impression from my prior seat on the action board in terms of bigger picture I think the fundamentals of action remain really strong. And in fact, I think they have only got stronger through 2025. So the ability to have an AI platform that is built up over many years, many iterations, grounded in data and testing that data in the lab and ultimately in the clinic has really strengthened the core offering. So I remain really excited about the power of the platform in the oncology space and also in the infectious disease space. And I think we're sort of seeing a lot more traction around what we can do with the platform now from external engagement. So I think the fundamental strengths and core of what Zivaction has to offer is even stronger now than potentially before. And I think in a world of AI everything, actually getting to products, actually producing candidates that can generate vaccines that generate a biological response and a clinical response is meaningful and is becoming recognized as meaningful certainly in our partnering conversations etc so i think that that uh is core so clear clear observation i had before coming into the company and certainly strengthened by all my observations within it um and even more impressed by the team that's in place that can deliver on this i think in terms of the overall strategy What Avaction does well is that early discovery, that early validation, that deep scientific and informatic embedded expertise. And we can certainly bring things forward into early clinical development, late preclinical, early clinical. And I think what we're going through at the moment is a process of really optimizing where we see the most value in the near term, both in terms of our oncology assets, but also within the infectious disease area. I think we are not positioned to take too much further forward into the clinic, so we're being very cautious about that. But we certainly see strength in getting interest from external parties around the assets that we've already got and actually the capability of the platform. So no fundamental change to strategy, but I think a sharpening and a deepening of focus around the assets that will add the most value. I hope that's helpful.

Yeah, that's great. Thank you, Helen. And just keying off of your last comment there about taking products into the clinic. You mentioned with EVX-04, or in Brigitte's presentation, that you would be looking to submit regulatory paperwork. Is that a product that you think you have to take into phase one, given that herbs are a bit new, a bit different, in order to attract partner interest?

I think that's a really good question. We are certainly preparing to take it into the clinic and we believe that we can do that to gain some initial proof of concept. There's a lot of interest around the platform at that particular set of candidate antigens in the vaccine. I think we're doing some further validation work, which I think will continue to strengthen it. So the answer in short is not necessarily, but clearly the more credible validating data that we can add to the package, the stronger the value proposition to an external partner. And that's obviously what we're all about, is maintaining the value, building the value for as long as we can to strengthen our position. And I think we're very confident about what we can do with it preclinically and potentially clinically.

That's great. Thank you very much.

Thank you. Thank you. Our next question today comes from the line of Michael Okunowicz from Maxine Group. Please go ahead.

Hi there. Thank you so much for taking my questions today, and congrats on all the great progress you've made. Thank you. I guess to start off, I'd just like to see if you could comment a little bit on the partnering efforts for EBX01. And in particular, if there's anything that you've heard either in your feedback from partners that you think yourself would be particularly important for us to watch for from the upcoming data releases, whether that's the three-year data or the biomarker immunogenicity, is there anything in particular you think is key for driving these partnering discussions?

So that's a really good question. And I mean, clearly the cancer vaccine space has had something of a checkered past way back, but more of a renaissance, I think, in the checkpoint era. And I think our data is certainly resonating with companies who are interested in the cancer vaccine area, understand the nuances around getting, I think, strong antigens, personalized cancer antigens for not just immune recognition, but for clinical benefit. So the It is a complex therapy to administer, but it is also potentially an effective therapy. And I think the sorts of things that gain interest are the, not just the response rate that we've seen at two years, one year, then two years at ESMO, but also the the recognition of the antigens, the numbers that you just spoke to in Alaska to add comments to this as well. So I think we're in a strong position with that clinical data package that we have, the translational data. I think it's going to be interesting. It continues to show why and how the immune response is happening in parallel to the clinical response. So that is, I think, a differentiator. and also in the population, the advanced population, rather than the adjuvant melanoma population. And clearly, I think we're also seeing interest in this whole approach in other high mutational burden cancers too, so beyond melanoma. I think those are the differentiators, thinking about where else this is applicable, acknowledging the different biological parameters, the translational insights that we're seeing that's somewhat different to how others have reported on this, with similar approaches. So quite a bit of interest. I think there are a number, to be honest, a number of companies are on the fence, but looking with interest and very interested in the shared approach, the shared action approach that our EBX04 program offers.

Birgitta, do you want to add some further comments? And so there's no doubt that the ability of our AI immunology platform to identify the relevant targets and is getting a lot of interest from potential partners and also from the academic community. And with this 81% hit rate, as we call it, I think this is very impressive. We have, of course, looked at other similar programs seen that most of them are reporting hit rates way below 60%, meaning that the antigens that they are including in their vaccines are not all able to induce a specific T cell response. And this is, of course, a testament to the precision of our platform. So that's one of the key elements And another point that I would like to make is that we do see EVX01 as not just a therapy for advanced melanoma. We believe that the same concept can be very useful in other indications where there are a high mutational burden, meaning that there are several antigens to choose from. And that includes many of the high prevalent conditions cancer indications. It could be non-small cell lung cancer and also some of the colorectal cancers.

Thank you. I appreciate that additional color on that.

And then as a follow-up, I wanted to ask if you could provide a bit more color on how you're applying the AI Immunology platform to autoimmune disease. You identified this as a new area of interest. And do you expect that this would be more focused on allergies or would you focus more on the major large autoimmune and inflammatory diseases? Any additional color you could provide on that would be helpful.

Sure. I think the first thing to say is it's early in terms of our prioritization of the indications, but we've certainly done some work around that based on parameters, which I'll, Vicky, if you're happy to comment on that, I think high level in terms of what's guiding

where we focus, that would be good.

Yes. So we have done a lot of analysis on the most prevalent autoimmune diseases, and we do see a clear fit for our platform. I mean, we, of course, need to further improve it and build a few additional smaller units that allows us to apply immunology. We do have many things in place that can be directly applied in this area. So we will, of course, share more when we have done both analysis on which key indications we will pursue and also when we have done a little bit more work on adjusting AI immunology so it fits these diseases. But we should remember to say that there's a lot of these smaller units, we call them building blocks, that we can directly apply for these types of diseases. So not only for autoimmune diseases, but also for other diseases where there is a strong immunological component. So, of course, we need to build a little bit, but the majority is already in AI immunology.

All right, thank you very much. I appreciate your additional comments and look forward to future updates.

Thank you. Thank you. Our next question today will come from the line of RK from HC Wainwright. Please go ahead.

Thank you. This is RK from HC Wainwright. Good afternoon, Helen, Brigada, and Tomas. to start off, Helen, a quick question for you. And, you know, you have, you know, basically been an architect and multi billion dollar alliances at that at that afternoon, you know, especially the large deal that was was transacted with GSK. And also, you have had a lot of experience in in transactions. And while Evaxion is technically a very strong company, they've always had a difficulty in translating that language into meaningful transactions. Of course, Merck is a pretty strong partner. Based on your experiences and how you have managed to translate that, You know, what sort of discussions could you have at this point, especially when talking with large cap pharma and convince them that an AI tool's predictability is as good as a physical assay and get them to start looking into some of the products that Evaxion is generating?

Hello, thanks for the question. I think there are probably multiple dimensions to answer that question to the extent that it is possible to answer it at this point. One is that a lot of this is to do with timing, it's to do with data that validates that it's more than a sort of an AI platform and I think actually the fact that we have the scope to validate and iterate candidate target discovery with candidate development, with candidate validation is something really novel that isn't generally out there. And when I said timing, there are obviously many of the large pharma, most of them will all have in-house AI platforms running in one form or another. But I don't think there are many that have got this sort of integrated longitudinal depths of expertise that have actually had. So really this is about crystallizing the offering through the validation of the candidates we have and sort of being in dialogue with the right people. And you mentioned my background was a long time, 17 years in my predecessor company, building relationships, establishing contact, understanding and listening to strategy, looking at the wider picture. These are all things that are very much part of how deals get done. And ultimately, it's down to relationships and credibility and really having something that fits the need. And all I can say at this point is we're reworking up some of those approaches and some of those themes in terms of how we are approaching potential partnering interactions. I have to say, though, that the Evaction Team as well with quite a few of these groups, but we're building and expanding that profile, and I think that's critical to, you know, the future success in partnering conversations. So it's being what you say you are in front of the right people.

Perfect. Thanks for that. Then going into relationships with Mark, especially regarding EVX B2, Merck decided to extend the evaluation of the molecule rather than exercise the option at this point. Is this a function of them trying to do additional experiments or functional assays, or are they requesting from you additional work so that they can come to a conclusion?

Sorry, you're referring to the extension that they had last year before the decision there. I mean, we can't really comment on obviously the combination nature of the interactions. All I can say is that sometimes it's sort of R&D programs when they are back and forth and shared between organizations don't always run to plan. And so sometimes that requires looking at things again. But ultimately, then, you know, there are timeframes around things which have to be followed through. So I think that the reasons for not taking up a sort of obviously their reasons and multi-dimensional. All I can say is that we remain really excited about the data. We actually continue to build data on the program internally throughout that period of time as well. So we feel very, very bullish and strong about the data package. you know, but how and why, you know, wanted to do, you know, certain work or is something we can't really, we can't really add any more commentary on.

Okay. On the EVX01's durability, Brigetta, so you have shown 92% of the responders showing sustainability at 24 months. As we are looking forward to the three-year durability, what sort of exhaustion markers are you going to be tracking so that we understand how well the durability is?

Yeah, thank you for that question, RK. So it's correct that 92% of the responders remained in response after this two-year mark. And I guess your question was related to the T cell extortion markers. Yes. We do a deep T cell profiling looking at activation marker, extortion markers, and also at different phenotypes of the T cells, so including CD4, CD8, but also looking into whether there are regulatory T cells coming up. And so far, we have demonstrated that the profile of the T cells are very favorable, so in more of the activation or effector type of cells and not not too many that are that are having exhaustion markers we also see that there's a like a dominance of cd40 cells and with some patients are also mounting a cd8 t cells by time so we have during this extension phase of the 30 we have been collecting additional blood samples that are currently being analyzed in our lab. So more to come on that. But it's very exciting. And since EVX01 is giving us immunotherapy in this extension phase, we're also very curious of understanding what EVX01 can drive on its own without having the background of the checkpoint inhibitors. OK.

And our next question comes from the line of Dania Ben-Hill from Jones.

Hi. Thank you for taking our question. On the autoimmune disease program, can you provide more detail on your strategy for validating early candidates? Thank you.

Thanks for the question. I mean, it's early, and we probably cannot provide more details, but Pegida, do you want to comment on how we think about it?

Yes, so the first step is to settle on an indication. So we've done landscaping, we've done dry analysis on looking at the top 10 most prevalent ultimate diseases, and we are now narrowing down which one could be the most, I would say, interesting from our perspective. whether it's a nice fit for AI immunology. And so that work is ongoing. We've almost completed it. And next step is to focus on building the additional smaller units that we will be needing in AI immunology to enable us to develop therapies for these diseases. And in parallel, we are also setting up mouse models in our lab, so ensuring that we can also test the candidates that AI immunology is designing. So that is the current plan. So pretty traditional way of analyzing or testing the candidates that AI immunology is designing.

Great. Thank you very much.

Thank you. This concludes today's question and answer session. I will now hand the call back to Ellen Tatian Martin, CEO, for closing remarks.

Thank you very much for everyone participating on the call today. It's been a great year for 2025 of transforming the company forward of action, delivering on multiple milestones and leaving us in a stronger financial position than for some time, where we hope we can take the company forward and deliver on our 2026 milestones and continue to strengthen the value that comes from the platform and the assets. So thank you for your questions and your engagement, and we look forward to our next update. Thank you. Bye-bye.